Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT01245374

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01245374
  • EudraCT 2009-017387-16
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01245374. Non-randomized; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2011-04 (actual). Results posted on 2012-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Condition
Growth Hormone Disorder
Condition
Growth Hormone Deficiency in Children
Condition
Foetal Growth Problem
Condition
Small for Gestational Age
Condition
Genetic Disorder
Condition
Turner Syndrome
Condition
Chronic Renal Insufficiency
Condition
Delivery Systems
Intervention (Device)
Norditropin NordiFlex®
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01245374
Content hash
e6df7a5734c50dd34214e04fb1d90b624020f93c6cd424d6c10777dc18d181e8